Predictive factors for concomitant pulmonary arterial hypertension at diagnosis of systemic lupus erythematosus in a Chinese population
- PMID: 34796660
- DOI: 10.1111/1756-185X.14251
Predictive factors for concomitant pulmonary arterial hypertension at diagnosis of systemic lupus erythematosus in a Chinese population
Abstract
Aim: To investigate the predictive factors of pulmonary arterial hypertension (PAH) in systemic lupus erythematosus (SLE) patients.
Method: This chart review study included 408 SLE patients. We defined PAH as 2 consecutive systolic pulmonary arterial pressure (PAP) values ≥40 mm Hg by echocardiography. Demographic characteristics, clinical symptoms, autoantibodies, and laboratory tests were studied.
Results: Thirty-four patients in the SLE/PAH+ group and 374 patients in the SLE/PAH- group were analyzed. The prevalence of PAH in SLE is 8.3% in this study. The occurrences of interstitial pneumonitis, polyserositis and myocardial damage were higher in the SLE/PAH+ group (P = .001, P = .033 and P < .001, respectively). The occurrence of anti-double-stranded DNA and anti-ribosomal RNA protein (anti-rRNP) antibodies were lower in the SLE/PAH+ group (P = .003, .010). Positive rates of anti-Sjögren's syndrome antigen A (anti-SSA)/Ro52 antibodies and anti-SSB antibodies were higher in the SLE/PAH+ group (P = .046, .021). C-reactive protein and immunoglobin G (IgG) were higher in the SLE/PAH+ group (P = .009, .005). Ejection fraction and SLE disease activity index between the 2 groups had no differences. Multivariable logistic regression indicated that interstitial pneumonitis, myocardial damage and high IgG are predictive factors for SLE-associated PAH patients.
Conclusion: From this study, we found that interstitial pneumonitis, myocardial damage, and high IgG were predictive factors of PAH in SLE patients.
Keywords: autoantibodies; predictive factors; pulmonary arterial hypertension; systemic lupus erythematosus.
© 2021 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Comment in
-
Comment on "Predictive factors for concomitant pulmonary arterial hypertension at diagnosis of systemic lupus erythematosus in a Chinese population".Int J Rheum Dis. 2022 Aug;25(8):966-967. doi: 10.1111/1756-185X.14398. Epub 2022 Jul 26. Int J Rheum Dis. 2022. PMID: 35880489 No abstract available.
Similar articles
-
Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: Baseline characteristics and risk factors.Int J Rheum Dis. 2019 May;22(5):921-928. doi: 10.1111/1756-185X.13478. Epub 2019 Feb 11. Int J Rheum Dis. 2019. PMID: 30746850
-
Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.Lupus. 2014 Sep;23(10):1085-91. doi: 10.1177/0961203314527366. Epub 2014 Mar 20. Lupus. 2014. PMID: 24651670
-
Right ventricular-pulmonary arterial coupling ratio derived from 3-dimensional echocardiography predicts outcomes in systemic lupus erythematosus-associated pulmonary arterial hypertension patients.Lupus. 2024 Feb;33(2):155-165. doi: 10.1177/09612033231226352. Epub 2024 Jan 5. Lupus. 2024. PMID: 38182135
-
Risk factors of systemic lupus erythematosus patients with pulmonary arterial hypertension: A systematic review and meta-analysis.Medicine (Baltimore). 2023 Dec 22;102(51):e36654. doi: 10.1097/MD.0000000000036654. Medicine (Baltimore). 2023. PMID: 38134088 Free PMC article.
-
Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review.Lupus Sci Med. 2022 Mar;9(1):e000636. doi: 10.1136/lupus-2021-000636. Lupus Sci Med. 2022. PMID: 35256456 Free PMC article. Review.
Cited by
-
Severe pulmonary arterial hypertension development despite lupus nephritis remission: association with podocytic infolding glomerulopathy.BMC Nephrol. 2025 Aug 30;26(1):503. doi: 10.1186/s12882-025-04428-1. BMC Nephrol. 2025. PMID: 40885899 Free PMC article.
-
Cathepsin S Inhibition Suppresses Experimental Systemic Lupus Erythematosus-Associated Pulmonary Arterial Remodeling.Int J Mol Sci. 2022 Oct 14;23(20):12316. doi: 10.3390/ijms232012316. Int J Mol Sci. 2022. PMID: 36293172 Free PMC article.
References
REFERENCES
-
- Pope J. An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it? Lupus. 2008;17:274-277.
-
- Wu G, Jia X, Gao D, Zhao Z. Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. Clin Rheumatol. 2014;33:947-953.
-
- Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a prisma-compliant systematic review and meta-analysis. Autoimmunity Rev. 2016;15:250-257.
-
- Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2(1):16039. 10.1038/nrdp.2016.39
-
- Condon D, Nickel N, Anderson R, Mirza S, de Jesus PV. The 6th World symposium on pulmonary hypertension: what's old is new. F1000Res. 2019;8:888.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials